

Chapter 196

Human Papilloma Virus Infections

Elliot J. Androphy & Reinhard Kirnbauer

REFERENCES

1. de Villiers EM et al: Classification of papillomaviruses. *Virology* **324**(1):17-27, 2004
2. Longworth MS, Laimins LA: Pathogenesis of human papillomaviruses in differentiating epithelia. *Microbiol Mol Biol Rev* **68**(2):362-372, 2004
3. Doorbar J: The papillomavirus life cycle. *J Clin Virol* **32**(Suppl 1):S7-S15, 2005
4. de Villiers EM, Whitley C, Gunst K: Identification of new papillomavirus types. *Methods Mol Med* **119**:1-13, 2005
5. Bernard HU, Calleja-Macias IE, Dunn ST: Genome variation of human papillomavirus types: Phylogenetic and medical implications. *Int J Cancer* **118**(5):1071-1076, 2006
6. Chan SY et al: Analysis of genomic sequences of 95 papillomavirus types: Uniting typing, phylogeny, and taxonomy. *J Virol* **69**(5):3074-3083, 1995
7. Bernard HU: The clinical importance of the nomenclature, evolution and taxonomy of human papillomaviruses. *J Clin Virol* **32**(Suppl 1):S1-S6, 2005
8. Majewski S, Jablonska S: Human papillomavirus-associated tumors of the skin and mucosa. *J Am Acad Dermatol* **36**(5 Pt 1):659-685; quiz 686-658, 1997
9. Munoz N et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med* **348**(6):518-527, 2003
10. Roberts JN et al: Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. *Nat Med* **13**(7):857-861, 2007
11. Kines RC et al: The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. *Proc Natl Acad Sci U S A* **106**(48):20458-20463, 2009
12. Wang Q et al: Functional analysis of the human papillomavirus type 16 E1-E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. *J Virol* **78**(2):821-833, 2004
13. Roden RB, Lowy DR, Schiller JT: Papillomavirus is resistant to desiccation. *J Infect Dis* **176**(4):1076-1079, 1997
14. Howett MK et al: A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. *Antimicrob Agents Chemother* **43**(2):314-321, 1999
15. Meyers C, Mayer TJ, Ozbun MA: Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. *J Virol* **71**(10):7381-7386, 1997
16. Fehrmann F, Laimins LA: Human papillomavirus type 31 life cycle: methods for study using tissue culture models. *Methods Mol Biol* **292**:317-330, 2005
17. Breitburd F et al: Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. *J Virol* **69**(6):3959-3963, 1995
18. Kirnbauer R et al: Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. *Virology* **219**(1):37-44, 1996
19. Berkhout RJ, Bouwes Bavinck JN, ter Schegget J: Persistence of human papillomavirus DNA in benign and (pre)malignant skin lesions from renal transplant recipients. *J Clin Microbiol* **38**(6):2087-2096, 2000
20. Moloney FJ et al: A population-based study of skin cancer incidence and prevalence in renal transplant recipients. *Br J Dermatol* **154**(3):498-504, 2006
21. Boxman IL et al: Detection of human papillomavirus types 6 and 11 in pubic and perianal hair from patients with genital warts. *J Clin Microbiol* **37**(7):2270-2273, 1999
22. Astori G et al: Human papillomaviruses are commonly found in normal skin of immunocompetent hosts. *J Invest Dermatol* **110**(5):752-755, 1998
23. Hazard K et al: Cutaneous human papillomaviruses persist on healthy skin. *J Invest Dermatol* **127**(1):116-119, 2007
24. Kilkenny M et al: The prevalence of common skin conditions in Australian school students: 1. Common, plane and plantar viral warts. *Br J Dermatol* **138**(5):840-845, 1998

25. Plunkett A et al: The frequency of common nonmalignant skin conditions in adults in central Victoria, Australia. *Int J Dermatol* **38**(12):901-908, 1999
26. Kokelj F et al: Study of the partners of women with human papillomavirus infection. *Int J Dermatol* **32**(9):661-663, 1993
27. Bleeker MC et al: Penile lesions and human papillomavirus in male sexual partners of women with cervical intraepithelial neoplasia. *J Am Acad Dermatol* **47**(3):351-357, 2002
28. Hogewoning CJ et al: Pearly penile papules: Still no reason for uneasiness. *J Am Acad Dermatol* **49**(1):50-54, 2003
29. Cohen BA, Honig P, Androphy E: Anogenital warts in children. Clinical and virologic evaluation for sexual abuse. *Arch Dermatol* **126**(12):1575-1580, 1990
30. Obalek S, Jablonska S, Orth G: Anogenital warts in children. *Clin Dermatol* **15**(3):369-376, 1997
31. Myhre AK et al: Anogenital human papillomavirus in non-abused preschool children. *Acta Paediatr* **92**(12):1445-1452, 2003
32. Baseman JG, Koutsky LA: The epidemiology of human papillomavirus infections. *J Clin Virol* **32**(Suppl 1):S16-S24, 2005
33. Schiffman M, Kjaer SK: Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. *J Natl Cancer Inst Monogr* (31):14-19, 2003
34. Partridge JM, Koutsky LA: Genital human papillomavirus infection in men. *Lancet Infect Dis* **6**(1):21-31, 2006
35. Wiatrak BJ et al: Recurrent respiratory papillomatosis: A longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. *Laryngoscope* **114**(11 Pt 2 Suppl 104):1-23, 2004
36. Puranen MH et al: Exposure of an infant to cervical human papillomavirus infection of the mother is common. *Am J Obstet Gynecol* **176**(5):1039-1045, 1997
37. Silverberg MJ et al: Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. *Obstet Gynecol* **101**(4):645-652, 2003
38. D'Souza G et al: Case-control study of human papillomavirus and oropharyngeal cancer. *N Engl J Med* **356**(19):1944-1956, 2007
39. Ramoz N et al: Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. *J Invest Dermatol* **114**(6):1148-1153, 2000
40. Ramoz N et al: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. *Nat Genet* **32**(4):579-581, 2002
41. Hama N, Ohtsuka T, Yamazaki S: Detection of mucosal human papilloma virus DNA in bowenoid papulosis, Bowen's disease and squamous cell carcinoma of the skin. *J Dermatol* **33**(5):331-337, 2006
42. Palefsky JM, Holly EA: Chapter 6: Immunosuppression and co-infection with HIV. *J Natl Cancer Inst Monogr* (31):41-46, 2003
43. Davison SC et al: Epidermodysplasia verruciformis-like eruption associated with HIV infection. *Clin Exp Dermatol* **29**(3):311-312, 2004
44. Soderlund-Strand A et al: Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. *J Clin Microbiol* **43**(7):3260-3266, 2005
45. Seme K et al: Digene HPV Genotyping RH Test RUO: comparative evaluation with INNO-LiPA HPV Genotyping Extra Test for detection of 18 high-risk and probable high-risk human papillomavirus genotypes. *J Clin Virol* **46**(2):176-179, 2009
46. Meyers C et al: Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. *Science* **257**(5072):971-973, 1992
47. Fang L et al: Induction of productive human papillomavirus type 11 life cycle in epithelial cells grown in organotypic raft cultures. *Virology* **347**(1):28-35, 2006
48. Thomas JT et al: Cellular changes induced by low-risk human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. *J Virol* **75**(16):7564-7571, 2001
49. Sherman L, Schlegel R: Serum- and calcium-induced differentiation of human keratinocytes is inhibited by the E6 oncoprotein of human papillomavirus type 16. *J Virol* **70**(5):3269-3279, 1996
50. Hawley-Nelson P et al: HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. *Embo J* **8**(12):3905-3910, 1989
51. Kaur P, McDougall JK: HPV-18 immortalization of human keratinocytes. *Virology* **173**(1):302-310, 1989

52. Oh ST, Longworth MS, Laimins LA: Roles of the E6 and E7 proteins in the life cycle of low-risk human papillomavirus type 11. *J Virol* **78**(5):2620-2626, 2004
53. Muench P et al: Binding of PDZ proteins to HPV E6 proteins does neither correlate with epidemiological risk classification nor with the immortalization of foreskin keratinocytes. *Virology* **387**(2):380-387, 2009
54. McLaughlin-Drubin ME, Munger K: Oncogenic activities of human papillomaviruses. *Virus Res* **143**(2):195-208, 2009
55. Fehrmann F, Laimins LA: Human papillomaviruses: Targeting differentiating epithelial cells for malignant transformation. *Oncogene* **22**(33):5201-5207, 2003
56. Ghittoni R et al: The biological properties of E6 and E7 oncoproteins from human papillomaviruses. *Virus Genes* **40**(1):1-13, 2010
57. Garnett TO, Duerksen-Hughes PJ: Modulation of apoptosis by human papillomavirus (HPV) oncoproteins. *Arch Virol* **151**(12):2321-2335, 2006
58. Munger K et al: Mechanisms of human papillomavirus-induced oncogenesis. *J Virol* **78**(21):11451-11460, 2004
59. Howie HL, Katzenellenbogen RA, Galloway DA: Papillomavirus E6 proteins. *Virology* **384**(2):324-334, 2009
60. McLaughlin-Drubin ME, Munger K: The human papillomavirus E7 oncoprotein. *Virology* **384**(2):335-344, 2009
61. Zhang B, Chen W, Roman A: The E7 proteins of low- and high-risk human papillomaviruses share the ability to target the pRB family member p130 for degradation. *Proc Natl Acad Sci U S A* **103**(2):437-442, 2006
62. Tungteakkhun SS, Duerksen-Hughes PJ: Cellular binding partners of the human papillomavirus E6 protein. *Arch Virol* **153**(3):397-408, 2008
63. Hiller T et al: Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. *Cancer Epidemiol Biomarkers Prev* **15**(7):1262-1267, 2006
64. Galloway DA et al: Regulation of telomerase by human papillomaviruses. *Cold Spring Harb Symp Quant Biol* **70**:209-215, 2005
65. Plug-DeMaggio AW et al: Telomere erosion and chromosomal instability in cells expressing the HPV oncogene 16E6. *Oncogene* **23**(20):3561-3571, 2004
66. Bedard KM et al: The E6 oncoproteins from human betapapillomaviruses differentially activate telomerase through an E6AP-dependent mechanism and prolong the lifespan of primary keratinocytes. *J Virol* **82**(8):3894-3902, 2008
67. Filippova M, Parkhurst L, Duerksen-Hughes PJ: The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. *J Biol Chem* **279**(24):25729-25744, 2004
68. Jackson S et al: Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. *Genes Dev* **14**(23):3065-3073, 2000
69. Leverrier S et al: Role of HPV E6 proteins in preventing UVB-induced release of pro-apoptotic factors from the mitochondria. *Apoptosis* **12**(3):549-560, 2007
70. Thomas M, Banks L: Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. *J Gen Virol* **80**(Pt 6):1513-1517, 1999
71. Underbrink MP et al: E6 proteins from multiple human betapapillomavirus types degrade Bak and protect keratinocytes from apoptosis after UVB irradiation. *J Virol* **82**(21):10408-10417, 2008
72. Freeman-Cook LL, Dimaio D: Modulation of cell function by small transmembrane proteins modeled on the bovine papillomavirus E5 protein. *Oncogene* **24**(52):7756-7762, 2005
73. Tsai TC, Chen SL: The biochemical and biological functions of human papillomavirus type 16 E5 protein. *Arch Virol* **148**(8):1445-1453, 2003
74. Palefsky J: Human papillomavirus-related disease in people with HIV. *Curr Opin HIV AIDS* **4**(1):52-56, 2009
75. Hamid NA, Brown C, Gaston K: The regulation of cell proliferation by the papillomavirus early proteins. *Cell Mol Life Sci* **66**(10):1700-1717, 2009
76. Mohr IJ et al: Targeting the E1 replication protein to the papillomavirus origin of replication by complex formation with the E2 transactivator. *Science* **250**(4988):1694-1699, 1990
77. Collins SI et al: Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: A longitudinal cohort study. *Cancer Res* **69**(9):3828-3832, 2009
78. Arias-Pulido H et al: Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. *J Clin Microbiol* **44**(5):1755-1762, 2006

79. Guo Z et al: Deletion of chromosome 3p is an early event in malignant progression of cervical cancer. *Anticancer Res* **18**(2A):707-712, 1998
80. Guo Z et al: Analysis of intratumoral heterogeneity of chromosome 3p deletions and genetic evidence of polyclonal origin of cervical squamous carcinoma. *Mod Pathol* **14**(2):54-61, 2001
81. Sherwood JB et al: Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants. *Gynecol Oncol* **79**(1):90-96, 2000
82. Singh RK et al: Deletions in chromosome 4 differentially associated with the development of cervical cancer: evidence of slit2 as a candidate tumor suppressor gene. *Hum Genet* **122**(1):71-81, 2007
83. zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. *Nat Rev Cancer* **2**(5):342-350, 2002
84. Bosch FX et al: The causal relation between human papillomavirus and cervical cancer. *J Clin Pathol* **55**(4):244-265, 2002
85. Alotaibi L et al: Diversity of cutaneous human papillomavirus types in individuals with and without skin lesion. *J Clin Virol* **36**(2):133-140, 2006
86. Purdie KJ et al: Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals. *J Invest Dermatol* **125**(1):98-107, 2005
87. Weissenborn SJ et al: Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers. *J Invest Dermatol* **125**(1):93-97, 2005
88. Iftner A et al: The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. *Cancer Res* **63**(21):7515-7519, 2003
89. Mahe E et al: High frequency of detection of human papillomaviruses associated with epidermodysplasia verruciformis in children with psoriasis. *Br J Dermatol* **149**(4):819-825, 2003
90. Boxman IL et al: Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. *J Invest Dermatol* **108**(5):712-715, 1997
91. de Koning MN et al: Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. *J Gen Virol* **90**(Pt 7):1611-1621, 2009
92. Forslund O et al: High prevalence of cutaneous human papillomavirus DNA on the top of skin tumors but not in "Stripped" biopsies from the same tumors. *J Invest Dermatol* **123**(2):388-394, 2004
93. Ruer JB et al: Detection of alpha- and beta-human papillomavirus (HPV) in cutaneous melanoma: a matched and controlled study using specific multiplex PCR combined with DNA microarray primer extension. *Exp Dermatol* **18**(10):857-862, 2009
94. Sterling JC: Human papillomaviruses and skin cancer. *J Clin Virol* **32**(Suppl 1):S67-S71, 2005
95. Majewski S, Jablonska S: Current views on the role of human papillomaviruses in cutaneous oncogenesis. *Int J Dermatol* **45**(3):192-196, 2006
96. Asgari MM et al: Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immunocompetent individuals. *J Invest Dermatol* **128**(6):1409-1417, 2008
97. Sterling JC, Handfield-Jones S, Hudson PM: Guidelines for the management of cutaneous warts. *Br J Dermatol* **144**(1):4-11, 2001
98. Lipke MM: An armamentarium of wart treatments. *Clin Med Res* **4**(4):273-293, 2006
99. Ahmed I et al: Liquid nitrogen cryotherapy of common warts: Cryo-spray vs. cotton wool bud. *Br J Dermatol* **144**(5):1006-1009, 2001
100. Connolly M et al: Cryotherapy of viral warts: A sustained 10-s freeze is more effective than the traditional method. *Br J Dermatol* **145**(4):554-557, 2001
101. Sawchuk WS et al: Infectious papillomavirus in the vapor of warts treated with carbon dioxide laser or electrocoagulation: Detection and protection. *J Am Acad Dermatol* **21**(1):41-49, 1989
102. Baker DA et al: Topical podofilox for the treatment of condylomata acuminata in women. *Obstet Gynecol* **76**(4):656-659, 1990
103. Salk RS, Grogan KA, Chang TJ: Topical 5% 5-fluorouracil cream in the treatment of plantar warts: A prospective, randomized, and controlled clinical study. *J Drugs Dermatol* **5**(5):418-424, 2006
104. Lewis TG, Nydorf ED: Intralesional bleomycin for warts: A review. *J Drugs Dermatol* **5**(6):499-504, 2006
105. Cha S et al: Treatment of verruca vulgaris with topical cidofovir in an immunocompromised patient: A case report and review of the literature. *Transpl Infect Dis* **7**(3-4):158-161, 2005

106. Toro JR et al: Topical cidofovir for the treatment of dermatologic conditions: Verruca, condyloma, intraepithelial neoplasia, herpes simplex and its potential use in smallpox. *Dermatol Clin* **21**(2):301-309, 2003
107. Buckley DA, Du Vivier AW: The therapeutic use of topical contact sensitizers in benign dermatoses. *Br J Dermatol* **145**(3):385-405, 2001
108. Holzer AM, Kaplan LL, Levis WR: Haptens as drugs: Contact allergens are powerful topical immunomodulators. *J Drugs Dermatol* **5**(5):410-416, 2006
109. Yilmaz E, Alpsoy E, Basaran E: Cimetidine therapy for warts: A placebo-controlled, double-blind study. *J Am Acad Dermatol* **34**(6):1005-1007, 1996
110. Reichman RC et al: Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: A double-blind, placebo-controlled trial. *J Infect Dis* **162**(6):1270-1276, 1990
111. Stanley MA: Imiquimod and the imidazoquinolones: Mechanism of action and therapeutic potential. *Clin Exp Dermatol* **27**(7):571-577, 2002
112. Gupta AK, Cherman AM, Tyring SK: Viral and non-viral uses of imiquimod: A review. *J Cutan Med Surg* **8**(5):338-352, 2004
113. Schofer H et al: Randomized, comparative trial on the sustained efficacy of topical imiquimod 5% cream versus conventional ablative methods in external anogenital warts. *Eur J Dermatol* **16**(6):642-648, 2006
114. Yaghoobi R, Sadighha A, Baktash D: Evaluation of oral zinc sulfate effect on recalcitrant multiple viral warts: A randomized placebo-controlled clinical trial. *J Am Acad Dermatol* **60**(4):706-708, 2009
115. Loureiro WR et al: Treatment of genital warts in men with potassium hydroxide. *Br J Dermatol* **158**(1):180-181, 2008
116. Clifton MM et al: Immunotherapy for recalcitrant warts in children using intralesional mumps or Candida antigens. *Pediatr Dermatol* **20**(3):268-271, 2003
117. Horn TD et al: Intralesional immunotherapy of warts with mumps, Candida, and Trichophyton skin test antigens: A single-blinded, randomized, and controlled trial. *Arch Dermatol* **141**(5):589-594, 2005
118. Ritter SE, Meffert J: Successful treatment of flat warts using intralesional Candida antigen. *Arch Dermatol* **139**(4):541-542, 2003
119. Brown VL et al: Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: Randomized, double-blind, placebo-controlled trial. *Arch Dermatol* **141**(8):985-993, 2005
120. Harwood CA et al: Low-dose retinoids in the prevention of cutaneous squamous cell carcinomas in organ transplant recipients: A 16-year retrospective study. *Arch Dermatol* **141**(4):456-464, 2005
121. Castellsague X et al: Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. *N Engl J Med* **346**(15):1105-1112, 2002
122. Winer RL et al: Condom use and the risk of genital human papillomavirus infection in young women. *N Engl J Med* **354**(25):2645-2654, 2006
123. Kirnbauer R et al: Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. *Proc Natl Acad Sci U S A* **89**(24):12180-12184, 1992
124. Harper DM et al: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. *Lancet* **367**(9518):1247-1255, 2006
125. Mao C et al: Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. *Obstet Gynecol* **107**(1):18-27, 2006
126. Villa LL et al: Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. *Vaccine* **24**(27-28):5571-5583, 2006
127. Villa LL et al: Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* **6**(5):271-278, 2005

